Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
AimsTo demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO).MethodsA 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123). All patien...
Alternative Titles
Full title
Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4893084
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4893084
Other Identifiers
ISSN
0007-1161
E-ISSN
1468-2079
DOI
10.1136/bjophthalmol-2015-307249
